Climb Bio, Inc.
Last verified 2026-05-05. JSON
| Total raised | $110.1M |
|---|---|
| Latest round | Funding round, $110.1M, 2026-05-04 |
| Founded | unknown |
| Headquarters | WELLESLEY HILLS, MA |
| Industry | bio |
| Stage | unknown |
| Website | climbbio.com |
Climb Bio develops monoclonal antibody treatments targeting immune-mediated diseases such as lupus, kidney disorders, and immune thrombocytopenia. It serves patients with limited therapeutic options needing disease-modifying medicines. Antibodies target specific immune pathways rather than relying on broad immunosuppression.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-05-04 | Funding round | $110.1M | undisclosed |
Detected tech stack
Cloudflare, WordPress, Yoast SEO 27.3, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, DoubleClick Floodlight, Cloudflare Bot Management, WP Engine, MailChimp, Underscore.js, Backbone.js
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $110.1M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Total raised $110.1M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Company existence | self-reported | climbbio.com, read 2026-05-05 |
| Description | self-reported | climbbio.com, read 2026-05-05 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $110.1M, 2026-05-04 → Funding round, $110.1M, 2026-05-04, SEC EDGAR, document, retrieved 2026-09-25 | Latest round | seed, $110.1M, 2026-05-04 → Funding round, $110.1M, 2026-05-04 | SEC EDGAR, document, retrieved 2026-09-25 |
| 2026-09-25Round: attributed → sourced, SEC EDGAR, document, retrieved 2026-09-25 | Round | attributed → sourced | SEC EDGAR, document, retrieved 2026-09-25 |
Records begin 2026-09-24. All changes